Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 9/20 | 0.51 |
| ▸ | MGLL | Q99685 | 5/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6114808 | 0.90 | ABHD6 (0.48) | ABHD6MGLLGPR119FAAHP2RX3 | |
| SCHEMBL31464380 | 0.90 | ABHD6 (0.48) | ABHD6MGLLGPR119FAAHP2RX3 | |
| SCHEMBL20345587 | 0.87 | ABHD6 (0.51) | ABHD6MGLLGPR119FAAHP2RX3 | |
| SCHEMBL22266021 | 0.84 | GPR119 (0.55) | GPR119HRH3ALDH1A1 | |
| SCHEMBL31312460 | 0.84 | GPR119 (0.55) | GPR119HRH3ALDH1A1 | |
| SCHEMBL31464571 | 0.84 | ABHD6 (0.46) | ABHD6MGLLGPR119FAAHP2RX3 | |
| SCHEMBL6115350 | 0.84 | ABHD6 (0.48) | ABHD6MGLLGPR119FAAHP2RX3 | |
| SCHEMBL18357554 | 0.82 | ABHD6 (0.53) | ABHD6MGLLGPR119P2RX3P2RX2 | |
| SCHEMBL2774468 | 0.82 | GPR119 (0.71) | GPR119HRH3ALDH1A1 | |
| SCHEMBL29799526 | 0.82 | RORC (0.47) | ABHD6MGLLGPR119P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-117295726-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2022223750-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | ABHD6 2296/4885MGLL 4524/4885GPR119 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.